Cancer Drugs Under Development

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Funding is the Greatest Need in Neuroendocrine Tumor Research

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.

Cristiane Decat Bergerot, PhD

April 14th 2025

Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

"These findings are particularly significant for Japanese patients, as our treatment options have been more limited compared to other regions," according to Keiji Inoue, MD, PhD, a professor in the Department of Urology at Kochi Medical School.

Russ Conroy

ctDNA May Help to Predict Early Recurrence in Stage III Melanoma

Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

ctDNA levels may help to predict early recurrence for patients with stage III melanoma before adjuvant therapy and during follow-up.

Related Content

Tim Cortese

April 23rd 2025

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Funding is the Greatest Need in Neuroendocrine Tumor Research

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.

Cristiane Decat Bergerot, PhD

April 14th 2025

Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Russ Conroy

ctDNA May Help to Predict Early Recurrence in Stage III Melanoma

Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.